A pharmacokinetic/pharmacodynamic model of ACE inhibition of the renin-angiotensin system for normal and impaired renal function

Abstract Angiotensin II (Ang II) is a hormone that regulates blood pressure and is produced by the renin-angiotensin system (RAS). Angiotensin converting enzyme (ACE) inhibitor drugs inhibit the production of Ang II. ACE inhibitors are well-characterized for use in hypertension, but they are not as well understood for use in chronic kidney disease. Existing models for ACE inhibitors have only been applied to normal renal function. Here, published experimental data for two ACE inhibitors (benazepril and cilazapril) in patients with normal and impaired kidneys are used to construct a pharmacokinetic model of the fate of drug doses in the circulatory system. A pharmacodynamic model connecting drug concentration to the inhibition of the RAS and production of Ang II is proposed and parameterized for the two drugs in the cases of normal and impaired renal function. The model is packaged as a MATLAB app to facilitate reuse for research and educational purposes.

[1]  C. Kawai,et al.  Studies on the Activation and Molecular Weight of Inactive Renin in Human Plasma , 1980, Hypertension.

[2]  D. Mager,et al.  Pharmacokinetic/Pharmacodynamic Modeling of Renin Biomarkers in Subjects Treated With the Renin Inhibitor Aliskiren , 2008, Clinical pharmacology and therapeutics.

[3]  D. Kirschner,et al.  A methodology for performing global uncertainty and sensitivity analysis in systems biology. , 2008, Journal of theoretical biology.

[4]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[5]  G. Stokes,et al.  DISAPPEARANCE RATE OF CIRCULATING RENIN AFTER BILATERAL NEPHRECTOMY IN THE RAT , 1974, Clinical and experimental pharmacology & physiology.

[6]  Anna Georgieva,et al.  Using a Systems Biology Approach to Explore Hypotheses Underlying Clinical Diversity of the Renin Angiotensin System and the Response to Antihypertensive Therapies , 2011 .

[7]  Xiping Xu,et al.  Elevation in Total Homocysteine Levels in Chinese Patients With Essential Hypertension Treated With Antihypertensive Benazepril , 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[8]  J. Sarver,et al.  Chapter 10 – Pharmacokinetic Modeling , 2009 .

[9]  H. V. Hamersvelt.  Pharmacokinetics and haemodynamic effects of the angiotensin converting enzyme inhibitor cilazapril in hypertensive patients with normal and impaired renal function , 2019 .

[10]  K. Goa,et al.  Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. , 1991, Drugs.

[11]  Maria C. Pruchnicki,et al.  Impact of Disease States on the Pharmacokinetics and Pharmacodynamics of Angiotensin‐Converting Enzyme Inhibitors , 2006, Journal of clinical pharmacology.

[12]  Sergej Ramusovic,et al.  An integrated Physiology-Based Model for the Interaction of RAA System Biomarkers With Drugs , 2012, Journal of cardiovascular pharmacology.

[13]  Jiří Zelinka,et al.  Kernel Density Estimation Toolbox for Matlab , 2011 .

[14]  Sergej Ramusovic,et al.  An integrated Physiology-Based Model for the Interaction of RAA System Biomarkers With Drugs , 2012, Journal of cardiovascular pharmacology.

[15]  K. Schulte,et al.  Clinical Pharmacokinetics of Angiotensin Converting Enzyme (ACE) Inhibitors in Renal Failure , 1993, Clinical pharmacokinetics.

[16]  G. Bakris,et al.  Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. , 2014, Advances in chronic kidney disease.

[17]  D. Vaughan,et al.  Angiotensin-converting enzyme inhibitors. , 1998, Circulation.

[18]  Y. Christen,et al.  Determinants of angiotensin II generation during converting enzyme inhibition. , 1990, Hypertension.

[19]  M. Minamisawa,et al.  Pharmacokinetics and Pharmacodynamics of Benazepril in Hypertensive Patients with Normal and Impaired Renal Function , 1992, Journal of cardiovascular pharmacology.

[20]  A. Danser,et al.  Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. , 1997, Hypertension.

[21]  F. Gengo,et al.  The pharmacokinetics of benazepril relative to other ace inhibitors , 1991, Clinical cardiology.

[22]  Jianping Wang,et al.  Protective effects of leflunomide on renal lesions in a rat model if diabetic nephropathy , 2016, Renal failure.

[23]  S. Hosoda,et al.  Effects of Nifedipine on Systemic and Pulmonary Vascular Impedance in Subjects Undergoing Cardiac Catheterization , 2006, Hypertension Research.

[24]  M. Schaller,et al.  Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers , 2004, European Journal of Clinical Pharmacology.

[25]  R. Gismondi,et al.  Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[26]  C. Atkins,et al.  Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs. , 2015, American journal of veterinary research.

[27]  Lucas G. Hill,et al.  ACE Inhibitors or ARBs to Prevent CKD in Patients with Microalbuminuria. , 2016, American family physician.

[28]  B. Waeber,et al.  Pharmacokinetics of the Converting Enzyme Inhibitor Cilazapril in Normal Volunteers and the Relationship to Enzyme Inhibition: Development of a Mathematical Model , 1987, Journal of Cardiovascular Pharmacology.

[29]  T. G. Coleman,et al.  Circulation: overall regulation. , 1972, Annual review of physiology.

[30]  H. O. Gulcur,et al.  Long-Term Mathematical Model Involving Renal Sympathetic Nerve Activity, Arterial Pressure, and Sodium Excretion , 2005, Annals of Biomedical Engineering.

[31]  Ashlee N. Ford Versypt,et al.  A Pharmacokinetic Simulation-Based Module to Introduce Mass Balances and Chemical Engineering Design Concepts to Engineering Freshmen , 2017 .

[32]  Y. Kaneko,et al.  Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function. , 1988, Journal of cardiovascular pharmacology.

[33]  Richard J. Beckman,et al.  A Comparison of Three Methods for Selecting Values of Input Variables in the Analysis of Output From a Computer Code , 2000, Technometrics.

[34]  C Revillard,et al.  [Clinical pharmacokinetics]. , 1976, Schweizerische medizinische Wochenschrift.

[35]  A. Layton,et al.  Bifurcation study of blood flow control in the kidney. , 2015, Mathematical biosciences.

[36]  P. Toutain,et al.  Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. , 2004, Journal of veterinary pharmacology and therapeutics.

[37]  D. Tarng,et al.  Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. , 2014, JAMA internal medicine.

[38]  Cathy A. Brown,et al.  Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency. , 2001, American journal of veterinary research.

[39]  L. Nie,et al.  Benazepril affects integrin-linked kinase and smooth muscle α-actin expression in diabetic rat glomerulus and cultured mesangial cells , 2014, BMC Nephrology.

[40]  A. Layton,et al.  Modeling Blood Flow Control in the Kidney , 2015 .

[41]  F. Guillaud,et al.  A Computational Model of the Circulating Renin-Angiotensin System and Blood Pressure Regulation , 2010, Acta biotheoretica.

[42]  T. Eissing,et al.  A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System , 2013, Front. Physio..

[43]  C. Désévaux,et al.  Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats , 2016, BMC Veterinary Research.

[44]  MN Trame,et al.  Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models , 2015, CPT: pharmacometrics & systems pharmacology.

[45]  J. Reid,et al.  The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension. , 1986, British journal of clinical pharmacology.

[46]  J. Elliott,et al.  Comparison of Efficacy of Long‐term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease , 2015, Journal of veterinary internal medicine.